Polycomb group (PcG) proteins are essential for development and are frequently misregulated in human cancers. Polycomb Repressive Complexes (PRC1, PRC2) function in a collaborative epigenetic cross-talk with H3K27me3 to initiate and maintain transcriptional silencing. Diffuse intrinsic pontine gliomas (DIPGs) have extremely low H3K27me3 levels mediated by H3 K27M oncohistone. Posterior fossa type A (PFA) ependymomas also exhibit very low H3K27 methylation but lack the K27M oncohistone. Instead, PFA tumors express high levels of EZHIP (Enhancer of Zeste Homologs Inhibitory Protein, also termed CXORF67). We find that a highly conserved sequence within the C-terminus of EZHIP is necessary and sufficient to inhibit the catalytic activity of PRC2 in vitro and in vivo. Our biochemical experiments indicate that EZHIP directly interacts with the active site of the EZH2 subunit in a mechanism that is remarkably similar to the K27M oncohistone. Furthermore, expression of H3 K27M or EZHIP in cells promote similar chromatin profiles: loss of broad H3K27me3 domains, but retention of H3K27me3 at the sites of PRC2 recruitment. Importantly, we find that H3K27me3-mediated allosteric activation of PRC2 substantially increases the inhibition potential of EZHIP and H3 K27M, providing a potential mechanism for loss of H3K27me3 spreading from CpG islands in vivo. Our data indicate that PFA ependymoma and DIPG are driven in part by the action of peptidyl PRC2 inhibitors-the K27M oncohistone and the EZHIP 'oncohistone-mimic'-that dysregulate gene silencing to promote tumorigenesis.
the original discovery, monoallelic missense mutations in genes encoding histone H3 have been found in a variety of solid tumors and leukemias [4] [5] [6] [7] . Previous studies have led to mechanistic insights into how one class of oncohistones promotes tumorigenesis by finding that lysine-tomethionine (K-to-M) substitutions transform histones from serving as substrates into specific and potent inhibitors of lysine methyltransferases. Approximately 84% of diffuse intrinsic pontine glioma (DIPG) and 60% of high-grade non-brainstem pediatric midline gliomas contain a lysine 27-methionine (K27M) mutation [1] [2] [3] . The H3 K27M oncohistone binds to and inhibits the catalytic subunit (EZH2) of the Polycomb Repressive Complex 2 (PRC2), a conserved protein complex involved in gene silencing [8] [9] [10] [11] [12] [13] [14] . Genome-wide profiling of H3K27me3 in H3 K27M-containing DIPG tumors and transgenic cell lines revealed a non-uniform reduction of H3K27me3 and, surprisingly, locus-specific K27M-dependent retention of this histone modification 8, [15] [16] [17] [18] [19] . While mechanistic questions related to H3 K27M remain, the unprecedented finding that oncohistones act as enzyme inhibitors and alter global levels of histone modifications in cells indicates a direct effect of chromatin misregulation driven by histone mutations in tumorigenesis.
A molecular subtype of ependymoma tumors exhibit extremely low H3K27 methylation levels similar to K27M-containing DIPG and midline gliomas. Ependymomas account for 10% of all pediatric tumors found in the central nervous system and can occur anywhere in the posterior fossa, spinal cord, or supratentorium 20 . Previous studies found that posterior fossa ependymomas comprise two distinct large molecular subclasses: PFA and PFB [21] [22] [23] . Compared to the PFB subgroup, PFA ependymomas exhibit H3K27me3 reduction and CpG islandhypermethylation similar to DIPG tumors containing the K27M oncohistone. Integrative analyses of genomic data sets from PFA and DIPG revealed that these two different tumor types share a common dysregulated chromatin landscape: global reduction of H3K27me3, but focal retention of H3K27me3 at CpG islands 21 . Unlike the vast majority of DIPGs, only 4.2% of PFA ependymomas contain the H3 K27M mutation 21, 24, 25 , and until recently it was unclear how the H3 wildtype PFA tumors achieved the aberrant DIPG-like chromatin profile.
A recent study uncovered that CXORF67, an uncharacterized gene whose expression is normally restricted to spermatogonia and encodes for an intrinsically disordered protein, is found at elevated levels in PFA ependymoma with poor prognosis 26 . CXORF67 expression was not detected in the small number of PFA ependymomas that contain the H3 K27M mutation, suggesting that these two tumor features are mutually exclusive. Additionally, CXORF67 protein co-immunoprecipitated with PRC2 subunits, and expression of CXORF67 led to a marked reduction in H3K27me3 in cultured cells 26 . Here, we describe the molecular mechanism by which CXORF67 reduces H3K27me3 levels in cells. We find that CXORF67 contains a highly conserved 'K27M-like' sequence that is necessary and sufficient to inhibit PRC2 activity and reduce cellular H3K27me3 levels. Using isogenic cell lines, we find remarkably similar genome-wide chromatin and gene expression changes caused by expression of H3 K27M or CXORF67. Our biochemical and cell-based studies demonstrate that CXORF67 functions as a K27M-like peptidyl inhibitor of PRC2. Therefore, we propose the name EZHIP (Enhancer of Zeste Homologs Inhibitory Protein) as a more descriptive name for the function of CXORF67. Additionally, we find that EZHIPexpressing PFAs and K27M-containing DIPGs aberrantly silence the CDKN2A tumor suppressor gene. We conclude that two biologically and clinically related brain tumors also share a common biochemical mechanism in tumorigenesis: inhibition of PRC2 activity through expression of potent peptide inhibitors.
RESULTS

EZHIP forms a stable complex with PRC2 and lowers H3K27me3 in vivo.
We sought to determine if EZHIP expression in ependymomas correlated with the previously noted DIPG-like chromatin profile 21 . Using previously published RNA and ChIP sequencing datasets 21 , we found that ependymoma tumors that express high levels of EZHIP also exhibit genome-wide reduction in H3K27me3 levels yet retain H3K27me3 at a subset of CpG islands ( Figure S1A, B) . This unique genome-wide H3K27me3 profile is remarkably similar to that observed in human DIPG tumors with the H3 K27M mutation ( Figure S1A ), suggesting that EZHIP and H3 K27M generate similar chromatin profiles in cells. To directly address whether EZHIP is sufficient to reduce H3K27 methylation levels, we generated human embryonic kidney-293T (HEK293T) cell lines that express FLAG epitope-tagged EZHIP, wildtype histone H3.3, H3.3 K27M or H3.3 K27R mutants. We found that expression of human EZHIP in HEK293T cell lines led to a similar overall decrease in H3K27me2/3 levels as measured by immunoblot and mass spectrometry ( Figure 1A , S1D). EZHIP may promote loss of H3K27me2/3 levels in cells through direct contact and inhibition of the EZH2 subunit of PRC2, as previously demonstrated for H3 K27M oncohistone 8, [10] [11] [12] [13] [14] . Conversely, EZHIP may reduce H3K27me2/3 levels through disruption of the integrity of the PRC2 complex. Previous studies have found that EZH2 levels depend on the integrity of PRC2 as the loss of SUZ12 or EED subunits dramatically reduces levels of EZH2 27 . Importantly, we found that the steady-state levels of PRC2 subunits were not altered in cells expressing EZHIP, suggesting that the PRC2 remains intact ( Figure S1C ). Therefore, we suspected that EZHIP promotes loss of H3K27me2/3 by contacting and modulating the activity of PRC2.
To identify the EZHIP-interacting proteins in cells, we immunoprecipitated EZHIP from HEK293T cell nuclear extract using anti-FLAG M2 beads. We assigned identities to the protein bands visualized by silver stain for the M2 eluate using immunoblotting ( Figure S1E and F). All core subunits of PRC2 such as EZH2, SUZ12, AEBP2, EED, and RBBP4/6 were found to associate with EZHIP ( Figure 1C , S1C-E). We confirmed co-immunoprecipitation of PRC2 subunits with EZHIP using mass spectrometry for protein identification ( Figure 1G ). Recent studies have revealed that the core PRC2 subunits associate with mutually exclusive combinations of auxiliary subunits [28] [29] [30] [31] . The PRC2.1 complex includes EPOP and the PCL proteins, while PRC2.2 associates with JARID2 and AEBP2 30, 31 . We found that EZHIP associates with both PRC2.1 and PRC2.2 as evidenced by co-immunoprecipitation of EZHIP with AEBP2, JARID2, LCOR, MTF2, PHF1, and PHF19 subunits ( Figure S1E ). Immunoprecipitated EZHIP co-fractionated with PRC2 subunits on Mono Q and Superdex 200 columns ( Figure 1B-F) . Additionally, we found that PRC2 subunits co-immunoprecipitated with EZHIP after washing with 1.0 M KCl buffers, further demonstrating a strong association between EZHIP and PRC2 ( Figure S1G ). Reciprocally, FLAG-epitope tagged EZH2 immunoprecipitated endogenous EZHIP from U2OS cells ( Figure S1H ).
Sequence algorithms predict no stable secondary structures in EZHIP, suggesting that the protein may be intrinsically disordered. EZHIP homologs are exclusively found in placental mammals and, with the exception of an invariant 12 amino acid sequence near the C-terminus, show little overall sequence conservation through most of the protein ( Figure 1H ). Despite little overall sequence similarity, we found that expression of murine EZHIP in HEK293T cells, and reciprocally, human EZHIP in murine embryonic fibroblasts (MEFs) led to decrease in H3K27me2/3 ( Figure 1I -J). These findings suggest that the conserved C-terminal sequence in EZHIP likely plays a central role in modulating PRC2 activity. Consistent with this hypothesis, a single amino acid substitution (R405E) in the conserved EZHIP peptide abolished the ability of EZHIP transgenes to lower H3K27me2/3 levels in HEK293T cells ( Figure 1K ). EZHIP missense mutations are found in 9.2% of PFA ependymomas and occur exclusively within a hotspot region in the poorly conserved N-terminus of protein. We found that EZHIP transgenes containing one of these mutations (D81Y) had no effect on H3K27me2/3 levels ( Figure 1J ). Similar results were recently reported for other EZHIP missense mutations found in PFA tumors 26 .
EZHIP is a competitive inhibitor of PRC2.
Taken together, our results suggest that EZHIP directly interacts with PRC2 and inhibits its lysine methyltransferase activity. To directly assess this proposition, we determined whether the recombinant EZHIP protein could inhibit PRC2 activity using in vitro methyltransferase assays. Titration of full-length, recombinant EZHIP to a methyltransferase reaction led to a dosedependent loss of PRC2 methylation of recombinant nucleosomes (IC50 = 50 nM) ( Figure 2A -B, S2A). Recombinant EZHIP containing the R405E substitution had a negligible effect on PRC2 activity in vitro (IC50 = NA). This finding directly links the loss of H3K27me2/3 levels in HEK293T cells with the ability of EZHIP to inhibit PRC2 activity in vitro. Interestingly, the absolutely conserved twelve residue sequence in the C-terminus of EZHIP is remarkably similar to the sequence surrounding lysine 27 in the histone H3 K27M peptide ( Figure 2C ). With the exception of methionine 406, the EZHIP conserved peptide is remarkably similar to the calculated 'optimal' substrate sequence previously defined for PRC2 32 . PRC2 has a noteworthy preference for an arginine at -1 position relative to the substrate lysine, while the identity of the residue at the +1 position is seemingly less critical for optimal activity 32 . We were able to model side chains of residues in the conserved EZHIP peptide on the H3K27M peptide observed in the PRC2-H3 K27M co-crystal structure without major steric hindrance 12 ( Figure S2B ). Interestingly, the critical R405 residue in EZHIP likely favorably interacts with D652 and Q648 of EZH2, whereas R407 was exposed to the solvent ( Figure 2D , S2C). These observations provide a structural and biochemical basis for our finding that R405E, but not R407E, abrogated PRC2 inhibition by EZHIP ( Figure 1J , 2B) and suggest that the EZHIP conserved sequence, henceforth referred to as K27M-Like Peptide (KLP), makes direct contacts with EHZ2 active site in a similar manner to the H3 K27M peptide.
The strong inhibition of PRC2 methyltransferase activity led us to determine the detailed mechanism of action and Michaelis-Menten kinetic parameters associated with nucleosome substrates as a function of EZHIP concentration. We found that EZHIP inhibition appears competitive on nucleosomes (Ki = 2.22 ± 4.2 nM), indicated by a linear dependence of the IC50 values on the concentration of substrate ( Figure 2E ). This inhibition constant of 2.22 ±0.4 nM is comparable to Ki of inhibition by H3 K27M nucleosomes (2.1 ±0.9 nM), 14 under similar reaction conditions.
The competitive mode of inhibition and the notable similarity between the KLP sequence to K27M and PRC2 substrates led us to hypothesize that EZHIP interacts directly with the active site of EZH2. Therefore, we reasoned that substituting a lysine for M406 would transform EZHIP into a PRC2 substrate. Indeed, we find that the full-length recombinant EZHIP M406K is a remarkably good substrate for PRC2, while the full-length M406A protein is not methylated by PRC2 to any measurable amount ( Figure 2F, S2E ). These data lead us to conclude that M406 binds to the active site of EZH2, likely through van der Waals interactions with a quartet of highly conserved aromatic residues lining the active site, and inhibits PRC2 through a K27M-like mechanism [12] [13] [14] 33, 34 . Previously, we found that histone H3 transgenes containing methionine or isoleucine at position 27 were capable of inhibiting PRC2 in vitro and decreasing H3K27me3 when expressed ectopically in cultured cells 13 . Similarly, we found that an EZHIP transgene containing isoleucine at M406, but not acidic (glutamic acid) or basic (lysine and arginine) amino acid substitutions, reduced H3K27me2/3 in cells to a similar extent as wildtype EZHIP ( Figure 2G ). These data further confirmed our conclusion that EZHIP conserved peptide interacts with the aromatic cage residues of EZH2 active site.
EZHIP KLP is sufficient and necessary to inhibit PRC2. Our in vitro and in vivo data indicate that a K27M-like peptide (KLP) in the C-terminus of EZHIP is necessary to inhibit PRC2 catalytic activity. We next sought to determine if the KLP was sufficient to inhibit PRC2 activity in vitro. To this end, we assessed recombinant PRC2 activity on histone H3 (18-37) peptide substrates in the presence of H3 K27M (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) or KLP (403-423) peptides ( Figure 3A , B). In this side-by-side comparison, we found that the KLP was a more potent inhibitor of PRC2 activity (IC50= 4.1 µM) than the H3 K27M peptide (IC50 = 27.87 µM). Consistent with the critical role of M406 for KLP function, a M406E peptide did not inhibit PRC2 activity in vitro ( Figure S1A ). Additionally, we found that the IC50 correlated positively with the peptide substrate concentration ( Figure 3D , S3B), a finding consistent with the competitive mode of inhibition that we found for full-length EZHIP and nucleosomal substrates ( Figure 2D , E). In addition to EZH2, mammals contain a second Enhancer of Zeste (Ez) homolog called EZH1 that complexes with PRC2 subunits and methylates H3K27 35, 36 . EZH1 peptides were identified in the EZHIP co-immunoprecipitated material that was analyzed by mass spectrometry ( Figure S1D ). We found that the KLP (IC50= 11.27 µM) and K27M (IC50= NA) inhibited EZH1-containing recombinant PRC2 in vitro ( Figure 3A , C).
Our previous studies revealed that methionine in the H3 K9M peptide occupies the active site of its cognate methyltransferase enzyme, G9a and forms a high-affinity ternary complex only in the presence of the co-substrate S-adenosyl methionine (SAM) 33 . Consistent with the formation of a ternary complex, kinetic analysis indicated that H3 K9M is an uncompetitive inhibitor of G9a with respect to SAM. We proposed that a SAM-induced conformational change allows the active site of the methyltransferases to stably interact with K-to-M histones found in human cancers. A similar SAM-dependent interaction between H3 K27M and PRC2 has also been described 12 . In addition to H3 K27M, we found that the KLP interacted with PRC2 in a SAM-dependent manner ( Figure 3E ) and that this association was abolished by the M406E substitution ( Figure S3C ). The KLP-PRC2 interaction was more stable than the K27M-PRC2 interaction at high NaCl concentrations. Together, these data suggest that a high affinity, SAMdependent ternary complex forms between SAM-bound PRC2 and EZHIP ( Figure S3D ). Consistent with our finding that the KLP interacts with the active site of EZH2, preincubation of PRC2 with H3 K27M and SAM abrogated PRC2 association with the KLP ( Figure S3E ).
Next, we synthesized a histone H3-EZHIP fusion protein to assess if the KLP, alone, in the context of the histone H3 tail could lower H3K27me2/3 levels in cells. We replaced residues 24-41 of histone H3 with EZHIP residues 403-420 spanning the KLP sequence. H3-EZHIP fusion transgenes containing methionine or isoleucine at residue 27 lowered global H3K27me2/3 levels, while substitution of lysine or arginine had no effect ( Figure 3G , S1B). Taken together, these data suggest that the K27M-like sequence in EZHIP is necessary and sufficient for PRC2 inhibition in vivo.
In our in vitro PRC2 assays, we observed that full-length EZHIP protein inhibits PRC2 at a lower concentration compared to KLP itself, suggesting the presence of a secondary PRC2 binding domain ( Figure S3F ). EZHIP is predicted to lack any secondary structure and KLP is flanked by intrinsically disordered regions (IDRs) containing short-tandem repeats, which are common in IDRs involved in protein-protein interactions (citation). We hypothesized that IDRs flanking KLP may facilitate EZHIP-PRC2 interaction and inhibition. To identify secondary PRC2 binding site within EZHIP, we generated a series of EZHIP deletion transgenes and assessed their potential to inhibit and bind PRC2 in vivo ( Figure 3H -I, S3G). We found that deletion of C-terminal or N-terminal residues from EZHIP (fragments 2, 3, 4, 6, 7) lowered H3K27me2/3 comparable to full-length EZHIP. An additional deletion of KLP from these transgenes (fragments 5, 8) abrogated its ability to inhibit and bind PRC2, underscoring the necessity of KLP for its activity. We observed that KLP by itself (fragments 9, 11) was unable to reduce H3K27me2/3 in vivo, mirroring its lower inhibitory potential in vitro compared to fulllength protein ( Figure S3F ). Interestingly, addition of either the C-terminal serine-rich IDRs or N-terminal short tandem repeats (fragments 4, 7, 10) significantly enhanced KLP binding and inhibition of PRC2. Since the flanking IDRs were unable to reduce H3K27me2/3 by themselves (fragments 5, 8) and were individually dispensable, we conclude that KLP is the primary PRC2 recognition and inhibitory domain within EZHIP and flanking IDRs enhance its inhibitory potential by making weak, non-specific interactions with PRC2.
To directly test the hypothesis that KLP is sufficient to lower H3K27me2/3 and utilizes flanking IDRs for strengthening EZHIP-PRC2 interaction, we synthesized an artificial protein containing KLP flanked by four intrinsically-disordered short, tandem repeats on each side ( Figure 3J ). We found that KLP sequence, but not M406E, embedded within flanking IDRs reduced H3K27me2/3 in vivo ( Figure 3K ). These data further support our conclusion that EZHIP KLP is sufficient to inhibit PRC2 in vivo.
EZHIP expression leads to K27M-like genomic distribution of H3K27me3
Expression of EZHIP transgenes caused a marked reduction in H3K27me2/3 in various cell types through inhibition of PRC2 activity in a K27M-like mechanism. We used chromatin immunoprecipitation followed by DNA sequencing (ChIP-Seq) and RNA sequencing to profile changes in gene expression and the chromatin landscape in MEFs expressing EZHIP. First, we generated MEF cell lines from E13.5 mouse embryo that contain loxP sites flanking exons 3-6 of the EED gene 37 . We used these MEF lines to derive isogenic transgenic H3.3 K27M and EZHIP cell lines to directly compare chromatin and gene expression changes caused by these two PRC2 inhibitor proteins. Cre-mediated excision of EED served as a control for chromatin and gene expression changes caused by genetic depletion of PRC2 in our MEF cell line.
Consistent with our mass spectrometry and immunoblot data, we observed a genomewide reduction of H3K27me3 in cells expressing H3.3 K27M or EZHIP as measured by the average normalized read counts of the immunoprecipitated chromatin ( Figure S5A , 4C). Additionally, EZHIP or H3.3 K27M expressing cells exhibited an 80% decrease in the total number of H3K27me3 peaks ( Figure S4A , B). Though some H3K27me3 peaks disappeared completely in EZHIP and H3.3 K27M cells, we noted a striking difference in distribution of H3K27me3 among the peaks that remained; while H3K27me3 is usually found in broad domains in wildtype cells, we noted that the peak width decreased substantially in cells expressing EZHIP or H3.3 K27M ( Figure 4A , B). Similar changes in H3K27me3 ChIP-seq profiles have been observed in DIPG cells containing the H3 K27M mutant histone 8, [15] [16] [17] [18] [19] . Previous studies demonstrated that PRC2 is allosterically activated via interaction of the EED subunit with either H3K27me3 or JARID2-K116me3 12, 38, 39 . These structural and biochemical studies found that the SET domain of EZH2 adopts a catalytically productive conformation when the EED subunit is engaged with the trimethylated H3K27 or JARID2-K116. Allosteric stimulation of PRC2 allows it to catalyze H3K27me3 on the neighboring nucleosomes in cis after initial recruitment to CpG islands, giving rise to broad H3K27me3 domains that are observed in vivo. Our ChIP-Seq data showed that EZHIP expression led to loss of H3K27me3 from secondary spread sites while retaining it at the recruitment sites. This loss of spreading led us to hypothesize that the allosterically activated form of PRC2 is more sensitive to inhibition by EZHIP. Indeed, we found that the H3.3 K27M (+K27me3 IC50 = 27.87 µM, compared toK27me3 IC50 = NA) and KLP (+K27me3 IC50 = 4.1 µM, compared to -K27me3 IC50 = 35.04 µM) inhibited allosterically activated PRC2 at a lower concentration in vitro ( Figure 4D ). A similar mechanism has been proposed for H3 K27M oncohistone where H3K27me3-bound PRC2 interacts with the H3 K27M peptide with higher affinity 12 . The genome-wide reduction of H3K27me3 led us to investigate whether the Polycomb Repressive Complex 1 (PRC1) distribution was altered by EZHIP or H3.3 K27M expression. Despite the overall decrease in H3K27me3 peak number and peak width, we found that the number and general distribution of PRC1 subunits CBX2 and RING1B remained unchanged by the expression of EZHIP or H3.3 K27M ( Figure 4E, S5C-D) . This finding suggests that the residual, H3K27me3-modified nucleosomes present in H3.3 K27M and EZHIP-expressing cells retain the capacity to recruit PRC1 complex.
We performed total RNA-sequencing to identify EZHIP-and H3 K27M-mediated changes in gene expression. Consistent with a loss of H3K27me3, we found up-regulation of ~500 genes in cells expressing EZHIP. Importantly, expression of H3 K27M or genetic depletion of PRC2 led to similar upregulation of these genes ( Figure 4F-G) . Specifically, we observed upregulation of silenced and lowly expressed genes that contains high levels of H3K27me3 in their promoters ( Figure 4G -H, S5E-F). Upregulation of these genes correlated with the loss of H3K27me3 from their promoters ( Figure 4G-H) . Together, our data show that expression of EZHIP or H3.3 K27M in an isogenic, cell culture system leads to a chromatin and gene expression profile that largely reflects loss of PRC2-mediated gene silencing.
Ependymomas expressing EZHIP display aberrant silencing of CDKN2A by increasing local H3K27me3.
Our in vivo experiments indicate that EZHIP and H3 K27M generate similar genomewide chromatin and gene expression profiles. We next analyzed H3K27me3 ChIP and RNA sequencing data from supratentorial (EZHIP negative, high H3K27me3) and PFA ependymomas (EZHIP positive, low H3K27me3). Our H3K27me3 ChIP sequencing analyses show that PFA ependymomas exhibit a similar chromatin profile to our MEFs expressing EZHIP; reduced peak width at all H3K27me3 peaks and a reduced number of total peaks ( Figure 5A, B) . We analyzed K27M-containing DIPG ChIP sequencing data and found a remarkable overlap in the location of residual H3K27me3 peaks found in K27M-containing DIPGs and PFA ependymomas ( Figure  5C ). These data support previously noted clinical and biological similarities between PFA ependymomas and DIPG tumors 21, 23, 40 .
We plotted the log2 expression profile of genes in PFA and supratentorial ependymomas to identify gene expression changes possibly caused by EZHIP expression ( Figure 5D , S5A) Using STRING analysis, we found enrichment of several gene ontology terms related to organism development and cell differentiation ( Figure S5B ). Earlier studies found that K27M-containing DIPGs exhibit global reduction in H3K27me3 and retention of H3K27me3 peaks at many genomic loci 8, [15] [16] [17] [18] [19] . The CDKN2A tumor suppressor gene is one locus that is silenced in a H3K27me3-dependent manner in K27M-containing DIPG cell lines and in H3.3 K27M glioma model systems 18, 41, 42 . Similarly, we found a 20-fold down-regulation of CDKN2A expression in PFA ependymomas. ChIP sequencing tracks show high levels of H3K27me3 at the CDKN2A locus in K27M-containing DIPG and EZHIP-expressing PFA ependymomas ( Figure 5E ). Additionally, ependymomas containing high EZHIP expression exhibit reduced levels of CDKN2A as compared to ependymomas with low EZHIP ( Figure 5F ). These results suggest that retention of PRC2 activity at CDKN2A in ependymomas expressing EZHIP may be a major contribution to tumorigenesis. Overall, these data support a model whereby chromatin-based silencing of tumor suppressors by mutation (K27M) or aberrant gene expression (EZHIP) facilitates formation two hindbrain tumor types (DIPG and PFA ependymomas).
DISCUSSION
In this study we demonstrated that expression of EZHIP, a putative driver of PFA ependymomas, lowers global H3K27me3 levels through inhibition of PRC2 methyltransferase activity. Our biochemical experiments show a direct and robust interaction with the core-PRC2 subunits. Moreover, the findings from our in vitro studies of EZHIP parallel results obtained from studies of the H3 K27M oncohistone found in DIPG and other high-grade midline gliomas. Both EZHIP and K27M contain short sequences that are potent competitive inhibitors of PRC2 in regard to the nucleosome substrate, interact with PRC2 in a SAM-dependent manner, and contain a critical methionine necessary for inhibition of PRC2 methyltransferase activity.
EZHIP homologs are found exclusively in placental mammals. Its expression pattern in normal development appears to be tightly restricted to spermatogonia, suggesting that the protein likely plays a role in spermatogenesis 43 . Genes involved in sexual reproduction have been noted to evolve rapidly, especially in rodents 44 . Interestingly, we find that EZHIP homolog sequences exhibit the most divergence among rodent species (Figure 1H) . EZHIP may have evolved to dynamically regulate PRC2 activity during spermatogenesis in mammals, and future studies will address questions related to the regulation of H3K27 methylation during spermatozoa development.
Missense mutations in EZHIP are reported in fewer than 10% of PFAs 26 . We found that missense mutations do not affect the H3K27 methylation lowering activity of EZHIP in vivo, suggesting that these tumor mutations do not alter the EZHIP protein function. Notably, nonsense or frameshift mutations that would alter the expression of the inhibitory EZHIP Cterminus have not been reported in PFA tumors. Instead, we hypothesize that the mutations promote expression of EZHIP through altering one or more cis-acting regulatory elements found within the gene body. Enhancers and other cis-acting genetic elements frequently occur within introns of genes. The EZHIP gene is, in all placental mammals, a long contiguous gene that lacks introns, thus functional mutations to intragenic regulatory elements will inadvertently alter the protein sequence. It is likely that PFA tumors that lack EZHIP mutations drive expression of the gene through other genetic or epigenetic mechanisms.
In addition to PFA ependymomas, EZHIP expression is implicated in uterine neoplasms, as a MBTD1-CXORF67 fusion gene was reported to occur in several endometrial stromal sarcomas 45 . Importantly, the MBTD1-CXORF67 fusion protein contains the C-terminus of EZHIP and the highly conserved K27M-like sequence, suggesting that PRC2 inhibition and loss of H3K27 methylation may support tumorigenesis of this subtype of endometrial cancer. In support of this model, other fusion proteins between PRC2 subunits and the zinc fingercontaining JAZF1 protein have been reported; JAZF1-PHF1 fusion proteins occur in a small number of endometrial stromal tumors, while a JAZF1-SUZ12 fusion protein reportedly occur in 75% of this tumor type that accounts for less than 10% of all uterine tumors [46] [47] [48] [49] . The JAZF1-SUZ12 protein is reported to dysregulate PRC2 activity and lower H3K27me3 levels in cells 46 . Curiously, no loss-of-function mutations of the core PRC2 subunits are reported to occur in pediatric DIPG or PFA ependymomas. On the contrary, multiple inactivating alleles of the PRC2 core subunits (EED and SUZ12) are reported in >80% of malignant peripheral nerve sheath tumors (MPNSTs) 50 . Based on these data, we previously hypothesized that some PcGmediated gene repression remains intact in cells expressing the K27M mutant histones, and that PRC2 activity is required for K27M-mediated transformation 34 . In support of residual PRC2 activity in cells, previously studies have found residual H3K27me3 in DIPG cells. Additionally, ChIP seq data from our isogenic cell lines revealed that expression of H3 K27M or EZHIP led to a reduction in total H3K27me3 peak numbers and peak width. The H3K27me3 nucleosomes retained at sites of PRC2 recruitment are functionally critical for DIPG growth as these cells are sensitive to pharmacological inhibitors of PRC2 18, 19 . We speculate that PFA-ependymomas that express high levels of EZHIP will also exhibit differential sensitivity to EZH2 inhibitors.
Previously, we and others have proposed that inhibition of PRC2 by H3 K27M prevents spreading of H3K27me3 into the secondary sites and intergenic regions, but allows its residual activity at primary, strong PRC2 sites at CpG islands 16, 18, 34 . This residual PRC2 activity is evident from an apparent local retention of residual H3K27me3 at specific loci. It is known that certain PTMs can positively or negatively regulate PRC2 methyltransferase activity, and the enzyme is stimulated by its own reaction product, namely H3K27me3 through interaction with the EED subunit 38 . In addition to serving as a possible recruitment mechanism, this feedforward mechanism is hypothesized to aid in establishing positive reinforcing loops that may facilitate spreading of H3K27me3 and Polycomb Repressive Complexes in cis. In contrast, the presence of the active chromatin marks, H3K4me3 and H3K36me3, each lead to a diminution in PRC2 activity [51] [52] [53] . These studies and others suggest that PRC2 is a dynamic signal integration device capable, through accessory subunits, of converting various inputs from the local chromatin context into an appropriate enzymatic output that ultimately allows controlled spreading of the polycomb transcriptionally silenced state.
In this study, we have observed that EZHIP has remarkably better inhibitory activity towards PRC2 that is allosterically activated by H3K27me3 (>8-fold difference in IC50 values). In the presence of high levels of H3K27me3, EZHIP efficiently inhibits stimulated-PRC2, leading to loss PRC2 spreading and an eventual recession of H3K27me3 back to sites of PRC2 recruitment. We speculate that EZHIP inhibitory activity directed towards PRC2 will diminish as H3K27me3 levels recede, allowing PRC2 to once again catalyze H3K27me3 on nucleosomes proximal to sites of recruitment. Hence, we propose EZHIP or K27M inhibition of PRC2, and its activity on nucleosomes are in a state of equilibrium that results in an optimal level of localized H3K27me3 conducive for PFA or DIPG development ( Figure 6 ). Cellular differentiation in normal development includes dynamic gain and loss of H3K27me3 at genes affecting cellular commitment. The expression of EZHIP or H3 K27M impairs the dynamic regulation of H3K27me3 by impeding its production by PRC2. The proposed cell-of-origin for PFA ependymomas is radial glia that serve as CNS progenitor cells, and a recent single cell sequencing study points to oligodendroglial progenitors as the likely cellof-origin for DIPGs 8, 21, 41, 54, 55 . Previous studies have found that H3 K27M impedes differentiation of neural precursor cells (NPCs) likely due to their inability to effectively silence genes involved in proliferation and multipotency 18, 41 . Additionally, these NPCs appear to adopt a more primitive stem state based on gene expression analysis. Here, we demonstrated that CDKN2A is silenced in EZHIP-expressing PFAs. CDKN2A encodes for critical regulators of the G1-S transition and is completely silenced in iPSCs and other stem cell populations 56 . While the gene is eventually activated during lineage commitment, the aberrant silencing of CDKN2A is known to contribute to DIPG tumorigenesis 18 . Future studies will address whether ectopic expression of EZHIP in radial glial cell populations lead to similar changes in gene expression and lineage commitment.
The sites of H3K27me3 found in PFA ependymomas and DIPG cells likely represent CpG islands that are the original recruitment sites for PRC2 in the cell-of-origin that gave rise to the tumor. We observed that a relatively small number of genes are dysregulated in EZHIP or H3 K27M expressing cells, despite the widespread reduction of H3K27me3 over many genes. We propose that many of these genes were not expressed due to redundant mechanisms of repression or by the inefficient transcription activation. We find that expression of H3 K27M or EZHIP lead to similar chromatin states and gene expression profiles in cells. While some PFA ependymomas contain the K27M mutation, EZHIP expression is the predominant mechanism for modulating PRC2 in these tumors. It is unknown whether DIPGs lacking the K27M mutation instead exhibit high levels of EZHIP expression. Additionally, it's unclear why PFAs and DIPGs seemingly exhibit a preference for EZHIP and H3 K27M, respectively.
In summary, we demonstrate that EZHIP inhibits PRC2 activity in a K27M-like mechanism. We propose that aberrant expression of EZHIP contributes to PFA ependymoma tumorigenesis through dysregulation of PRC2-mediated gene repression. Defining the molecular pathways involved in mediating the oncogenic potential of EZHIP will identify therapeutic targets that may improve disease management and outcome.
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Data Availability
The sequencing data reported in this paper are deposited at GEO database (GSE124839, GSE124743). Published data used in this paper were downloaded from GEO (GSE87779, GSE89452, and GSE118954). Raw mass spectrometry data reported in this paper have been deposited at ProteomeXchange (Accession ID: PXD013117). Schematic depicting the molecular mechanism by which EZHIP expression leads to the loss of H3K27me3 spreading. In cells lacking EZHIP expression (in blue), PRC2 is recruited to CpG islands and catalyzes H3K27me3 at recruitment sites. H3K27me3-marked nucleosomes proximal to the recruitment site allosterically activate PRC2 and promote spreading in cis to form broad H3K27me3 domains. Similarly, in cells expressing EZHIP (red), PRC2 is recruited to CpG islands and can catalyze H3K27me3 at proximal nucleosomes due the weaker inhibition potential of EZHIP for unstimulated PRC2. However, spreading of H3K27me3 is blunted due to enhanced binding of EZHIP to allosterically stimulated PRC2. The formation of H3K27me3-PRC2-EZHIP ternary complex leads to inhibition of PRC2 spreading and provides a mechanism to explain the formation of narrow H3K27me3 peaks found in PFA ependymomas. Figure 3E with EZHIP WT or M406E peptides (403-423). (D) Peptide pulldowns were performed as described in Figure 3E , with increasing concentrations of NaCl for washes. (E) Peptide pulldowns were performed as described in Figure 3E , except PRC2 was pre-incubated with 37.5 µM of either H3K27M 1-42 or 3x-FLAG peptide in the presence of 40 µM SAM before addition of biotinylated-EZHIP peptide and beads. (F) In vitro PRC2 assays using native PRC2 and oligonucleosome substrate as described in Figure 2B in the presence of increasing concentrations of full-length EZHIP or EZHIP peptide (403-423). (G) Immunoblots of eluates from FLAG M2 immunoprecipitation from nuclear extracts of 293T cells overexpressing FLAG-tagged full length EZHIP or EZHIP fragments (1, 2, 4, 5, 8, 9 , 10, 11) as shown in Figure 3H . KCl (mM): 300 500 750 1000 αEED αFLAG 
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Materials and Methods
Cloning
Human and mouse EZHIP gene was cloned from genomic DNA isolated from 293T and MEF cells respectively. The protein sequences used in this study are described below.
Transgenic Cell line generation
Mouse embryonic fibroablasts (MEFs) used in this study were isolated from E13.5 day embryo that contain loxP sites flanking exons 3-6 of the EED gene (Xie et al., 2014) . Human 293T, 293F or Mouse Embryonic Fibroblasts (MEFs) cells were transduced with recombinant lentiviruses produced using pCDH-EF1a-MCS-Puro expression vector. Transduced cells were selected with 1 µg/ml of puromycin for 4 days and harvested for immunoblot analysis after 6-10 days.
Histone extraction
Cells were lysed in hypotonic lysis buffer (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.5mM PMSF, 0.1% TritonX-100. Chromatin pellet was incubated in 0.4N H2SO4 overnight at room temperature. Histones were precipitated from the supernatant using 33% TCA, washed in acetone and resuspended in water.
Histone derivatization and PTM analysis by nano-LC-MS
Acid-extracted histones (5-10 μg) were resuspended in 100 mM ammonium bicarbonate (pH 8), derivatized using propionic anhydride and digested with trypsin as previously described (26) . The resulting histone peptides were desalted using C18 Stage Tips, dried using a centrifugal evaporator, and reconstituted using 0.1 M acetic acid in preparation for LC-MS analysis. The samples were loaded onto a trap column (75 µm x 2 cm, 3 µm, ReproSil-Pur 120 C18-AQ, Dr. Maisch GmbH) using an Eksigent AS2 autosampler. Histone peptides were resolved on an analytical column (75 µm x 15 cm, 3 µm ReproSil-Pur 120 C18-AQ) using a two-step gradient from 2% ACN to 30% ACN in 0.1% formic acid over 40 min, then from 30% ACN to 95% ACN in 0.1% formic acid over 20 min at a flow rate of 250 nL/min using an Eksigent nanoLC-Ultra 2D. The HPLC was coupled to an Orbitrap Elite mass spectrometer. Full-MS spectra (290-1600 m/z) were collected using a resolution of 60,000 and an AGC target value of 1x10 6 in the orbitrap. Lock mass calibration in full MS scans was enabled using polysiloxane ions at 371.1012 and 445.1200 m/z. MS/MS data was collected using targeted scans against H3 and H4 peptides in addition to data-dependent scans using collision activated dissociation (CAD) and an AGC target value of 1x10 4 in the ion trap. Dynamic exclusion was enabled with an exclusion time of 30 s. Singly-charged ions and ions without a detectable charge state were excluded from fragmentation. Mass-to-charge ratios were calculated for each modified form of H3 and H4 peptides, including the H3.3 (27-40) peptide containing the K36M mutation. Data from all detectable charge states were summed. The area under the curve was calculated from extracted ion chromatograms using Xcalibur Qual Browser for each histone peptide mass-to-charge ratio using a 10 ppm mass accuracy cutoff. The area for each modification state of a peptide was normalized against the total peptide signal to give the relative abundance of the histone modification. Each histone sample was injected three times on the MS, and the relative abundance of each peptide modification was averaged across the runs.
